Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.85
- Piotroski Score 1.00
- Grade Neutral
- Symbol (RETA)
- Company Reata Pharmaceuticals, Inc.
- Price $172.36
- Changes Percentage (0.02%)
- Change $0.04
- Day Low $172.32
- Day High $172.46
- Year High $172.46
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2023
- Fiscal Year End N/A
- Average Stock Price Target $46.00
- High Stock Price Target $115.00
- Low Stock Price Target $27.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.60
- Trailing P/E Ratio -66.292307692308
- Forward P/E Ratio -66.292307692308
- P/E Growth -66.292307692308
- Net Income $-311,901,000
Income Statement
Quarterly
Annual
Latest News of RETA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Up 31% in September, can this discount retailer keep gaining big?
September has brought volatility to the market, with S&P 500 experiencing significant swings. Five Below stock surged by 31%, benefiting from strong sales and analyst updates. Investors can access AI-...
By Yahoo! Finance | 16 hours ago -
THG Mulls Logistics Unit Spinoff, Pretax Loss Narrows
The Hut Group (THG) plans to spin off its logistics arm, THG Ingenuity, to enhance shareholder value. The U.K. e-commerce company reported a reduced pretax loss and aims to shift its listing category ...
By MarketWatch | 19 hours ago -
Ukraine war briefing: Russia retakes two villages in Kursk as counteroffensive continues, Moscow says
Ukraine blacklisted the director of a controversial war documentary for spreading Russian propaganda about Moscow's invasion. Meanwhile, the trial of a French citizen in Russia for collecting military...
By The Guardian | 1 day ago
